Baxter’s Hyland Plans Hemophilia Treatment
- Share via
Baxter Healthcare’s Glendale-based Hyland division said it entered into a licensing agreement with Genentech Inc., a San Francisco biotechnology company, to co-develop and market a hemophilia treatment. The treatment will use recombinant tissue factor, a blood-clotting component, to help hemophiliacs who don’t respond to the usual therapy for making blood coagulate.
Terms of the joint venture weren’t disclosed. The Hyland division will conduct clinical trials beginning next year, and Genentech will produce the treatment, Baxter said. The treatment could potentially be used on 10% to 20% of the 80,000 hemophiliacs worldwide, it said.
Baxter Healthcare is a Deerfield, Ill., health-care products and services concern with $7.4 billion in revenues in 1989.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
